BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Clinical Outcome
23 results:

  • 1. Epigenetic upregulation of MNAT1 by SMYD2 is linked to PI3K/akt activation and tumorigenesis of pancreatic adenocarcinoma.
    Xu Z; Liu Y; Pan Z; Qin L
    Histol Histopathol; 2024 Feb; 39(2):263-277. PubMed ID: 37232506
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation.
    Yang Z; Xie H; Wan J; Wang Y; Zhang L; Zhou K; Tang H; Zhao W; Wang H; Song P; Zheng S
    EBioMedicine; 2023 Jun; 92():104594. PubMed ID: 37167784
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Activation of the PI3K-akt signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells.
    Deng S; Zhang L; Li J; Jin Y; Wang J
    Tissue Cell; 2022 Jun; 76():101756. PubMed ID: 35217388
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in pancreatic Ductal Adenocarcinoma.
    Zhang Y; Liu Q; Cui M; Wang M; Hua S; Gao J; Liao Q
    Front Immunol; 2021; 12():774435. PubMed ID: 35046938
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer.
    Nicolle R; Blum Y; Duconseil P; Vanbrugghe C; Brandone N; Poizat F; Roques J; Bigonnet M; Gayet O; Rubis M; Elarouci N; Armenoult L; Ayadi M; de Reyniès A; Giovannini M; Grandval P; Garcia S; Canivet C; Cros J; Bournet B; Buscail L; ; Moutardier V; Gilabert M; Iovanna J; Dusetti N
    EBioMedicine; 2020 Jul; 57():102858. PubMed ID: 32629389
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Deoxycholic acid modulates the progression of gallbladder cancer through N
    Lin R; Zhan M; Yang L; Wang H; Shen H; Huang S; Huang X; Xu S; Zhang Z; Li W; Liu Q; Shi Y; Chen W; Yu J; Wang J
    Oncogene; 2020 Jun; 39(26):4983-5000. PubMed ID: 32514152
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic pancreatic cancer.
    Nair N; Chen SY; Lemmens E; Chang S; Le DT; Jaffee EM; Murphy A; Whiting C; Müller T; Brockstedt DG
    Cancer Immunol Res; 2020 May; 8(5):609-617. PubMed ID: 32132105
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Valproic Acid Addresses Neuroendocrine Differentiation of LNCaP Cells and Maintains Cell Survival.
    Giordano F; Naimo GD; Nigro A; Romeo F; Paolì A; De Amicis F; Vivacqua A; Morelli C; Mauro L; Panno ML
    Drug Des Devel Ther; 2019; 13():4265-4274. PubMed ID: 31908413
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Identification of a 4-miRNA signature as a potential prognostic biomarker for pancreatic adenocarcinoma.
    Wang ZX; Deng TX; Ma Z
    J Cell Biochem; 2019 Oct; 120(10):16416-16426. PubMed ID: 31297864
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like properties by modulating forkhead box protein M1.
    Cao J; Li J; Sun L; Qin T; Xiao Y; Chen K; Qian W; Duan W; Lei J; Ma J; Ma Q; Han L
    Mol Oncol; 2019 Feb; 13(2):228-245. PubMed ID: 30367545
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
    Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
    J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Asporin promotes pancreatic cancer cell invasion and migration by regulating the epithelial-to-mesenchymal transition (EMT) through both autocrine and paracrine mechanisms.
    Wang L; Wu H; Wang L; Zhang H; Lu J; Liang Z; Liu T
    Cancer Lett; 2017 Jul; 398():24-36. PubMed ID: 28400334
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial.
    Maltoni M; Scarpi E; Dall'Agata M; Zagonel V; Bertè R; Ferrari D; Broglia CM; Bortolussi R; Trentin L; Valgiusti M; Pini S; Farolfi A; Casadei Gardini A; Nanni O; Amadori D;
    Eur J Cancer; 2016 Sep; 65():61-8. PubMed ID: 27472648
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Prolonged survival in pancreatic cancer patients with increased regucalcin gene expression: Overexpression of regucalcin suppresses the proliferation in human pancreatic cancer MIA PaCa-2 cells in vitro.
    Yamaguchi M; Osuka S; Weitzmann MN; El-Rayes BF; Shoji M; Murata T
    Int J Oncol; 2016 May; 48(5):1955-64. PubMed ID: 26935290
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites.
    Di Gangi IM; Mazza T; Fontana A; Copetti M; Fusilli C; Ippolito A; Mattivi F; Latiano A; Andriulli A; Vrhovsek U; Pazienza V
    Oncotarget; 2016 Feb; 7(5):5815-29. PubMed ID: 26735340
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Polymorphisms in epidermal growth factor receptor (EGFR) and akt1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
    Zhang X; Fan J; Li Y; Lin S; Shu P; Ni J; Qin S; Zhang Z
    Tumour Biol; 2016 Jan; 37(1):1061-9. PubMed ID: 26269114
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Reverse-phase protein array analysis to identify biomarker proteins in human pancreatic cancer.
    Huang YJ; Frazier ML; Zhang N; Liu Q; Wei C
    Dig Dis Sci; 2014 May; 59(5):968-75. PubMed ID: 24248418
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Novel synthetic oleanane triterpenoid AMR-MeOAc inhibits K-Ras through ERK, akt and survivin in pancreatic cancer cells.
    Rabi T; Venkatanarashiman M
    Phytomedicine; 2014 Mar; 21(4):491-6. PubMed ID: 24215674
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Anti-pancreatic cancer deliverables from sea: first-hand evidence on the efficacy, molecular targets and mode of action for multifarious polyphenols from five different brown-algae.
    Aravindan S; Delma CR; Thirugnanasambandan SS; Herman TS; Aravindan N
    PLoS One; 2013; 8(4):e61977. PubMed ID: 23613993
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Ultraviolet enhances the sensitivity of pancreatic cancer cells to gemcitabine by activation of 5' AMP-activated protein kinase.
    Adachi S; Yasuda I; Kawaguchi J; Yamauchi T; Nakashima M; Itani M; Nakamura M; Yoshioka T; Moriwaki H; Kozawa O
    Biochem Biophys Res Commun; 2011 Oct; 414(1):53-9. PubMed ID: 21945432
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.